New facility in Texas will have capabilities for process and analytical development and manufacturing services for CAR-T, IPSC, MSC and cell therapies.
Projects include upgrades to existing analytical services, the installation of new equipment, including reactors, filter dryers, and distillation units.
Offers analytical method validation and analytical services to support batch release, in additional to stability studies to enable rapid regulatory filing.
Expands sterile capacity at Latina, Italy site for fill/finish vials and PFS; to close Wolfratshausen site and discontinue sterile manufacturing at Gronau site.
Combines virtual executive leadership and program management with industry-leading capabilities and capacity for development and manufacturing of therapies.
Aims to enable the generation of high quality material and data in under five months to move rapidly towards IND approval and GMP clinical manufacturing.
CBM will manufacture and partner with Virion on their checkpoint modifier clinical development programs, including the First-in-Human VRON-0200 immunotherapy.